Tislelizumab-jsgr (Tevimbra)
Dilution requiredFull monograph review pending
U.S. label preparation
Tevimbra · Dilution required
- Preparation
- Transfer the prescribed volume into 0.9% sodium chloride to reach 2-5 mg/mL. Gently invert.
- Administration and handling
- Use the labeled low-protein-binding 0.2- or 0.22-micron filter.
Product and source details
BeOne Medicines USA, Inc. · BLA761232
Product NDC: 72579-121, 72579-125
SPL effective 2026-09-01 | SPL version 15. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.